As part of Novartis’ continued commitment to medical education in rheumatology. Join our faculty as they discuss:
- The disease state of JPsA and ERA and the impact of diagnosis, clinical features, and disease activity on patients and caregivers
- The importance of both the patient perspective and the unmet needs for optimizing the management of JPsA and ERA
- Clinical evidence for IL17 inhibition in the management of ERA and JPsA
This presentation was supported by Novartis.
